Hepatic microbiome in healthy lean and obese humans

Autor: Malte Palm Suppli, Jonatan Ising Bagger, Benjamin Lelouvier, Amandine Broha, Mia Demant, Merete Juhl Kønig, Charlotte Strandberg, Asger Lund, Tina Vilsbøll, Filip Krag Knop

Publikováno v: JHEP Reports, Vol 3, Iss 4, Pp 100299- (2021)

Background & Aims: Dysbiosis of the gut microbiota in response to an energy-rich Western diet and the potential leak of bacteria and/or bacterial products from the intestine to the liver is perceived as a potential risk factor for the development of

Externí odkaz: https://doaj.org/article/a0196d97fb6e4e1b998666e0f93559f2

Long-term integrity of 53 iliac vein stents after catheter-directed thrombolysis

Autor: Pia Foegh, Charlotte Strandberg, Sanne Joergensen, Peter S Myschetzky, Lotte Klitfod, Sven Just, Susanne Hansen, Niels Baekgaard

Publikováno v: Acta radiologica (Stockholm, Sweden : 1987).

Background Long-term surveillance data on venous stent integrity is sparse. There is limited knowledge on whether duplex ultrasound (DUS) can detect potential stent deformities such as kinking, straightening, and fracture, which may impact long-term

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c50b0425cdf94f990eee9ba05fd5d355
https://pubmed.ncbi.nlm.nih.gov/35404166

Hepatic microbiome in healthy lean and obese humans

Autor: Jonatan I. Bagger, Tina Vilsbøll, Filip K. Knop, Benjamin Lelouvier, Malte P. Suppli, Charlotte Strandberg, Amandine Broha, Mia Demant, Merete J Kønig, Asger Lund

Publikováno v: JHEP Reports, Vol 3, Iss 4, Pp 100299-(2021)
JHEP Reports
Suppli, M P, Bagger, J I, Lelouvier, B, Broha, A, Demant, M, Kønig, M J, Strandberg, C, Lund, A, Vilsbøll, T & Knop, F K 2021, ' Hepatic microbiome in healthy lean and obese humans ', JHEP Reports, vol. 3, no. 4, 100299 . https://doi.org/10.1016/j.jhepr.2021.100299

Background & Aims Dysbiosis of the gut microbiota in response to an energy-rich Western diet and the potential leak of bacteria and/or bacterial products from the intestine to the liver is perceived as a potential risk factor for the development of n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23eee827bacdf1b0e217e24af3bd81a5
http://www.sciencedirect.com/science/article/pii/S2589555921000756

One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial

Autor: Camilla Andreasen, Jens J. Holst, Signe Foghsgaard, Louise Vedtofte, Lise Lotte Gluud, Jens Svare, Tina Vilsbøll, Jonatan I. Bagger, Tine D. Clausen, Charlotte Strandberg, Peter M Gørtz, Peter Damm, Emilie Bahne, Filip K. Knop, Henning Grønbæk, Elisabeth R. Mathiesen

Publikováno v: Vedtofte, L, Bahne, E, Foghsgaard, S, Bagger, J I, Andreasen, C, Strandberg, C, Gortz, P M, Holst, J J, Gronbaek, H, Svare, J A, Clausen, T D, Mathiesen, E R, Damm, P, Gluud, L L, Knop, F K & Vilsboll, T 2020, ' One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial ', Journal of Clinical Medicine, vol. 9, no. 10, 3213 . https://doi.org/10.3390/jcm9103213
Journal of Clinical Medicine, Vol 9, Iss 3213, p 3213 (2020)
Journal of Clinical Medicine
Volume 9
Issue 10
Vedtofte, L, Bahne, E, Foghsgaard, S, Bagger, J I, Andreasen, C, Strandberg, C, Gørtz, P M, Holst, J J, Grønbæk, H, Svare, J A, Clausen, T D, Mathiesen, E R, Damm, P, Gluud, L L, Knop, F K & Vilsbøll, T 2020, ' One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial ', Journal of Clinical Medicine, vol. 9, no. 10, 3213 . https://doi.org/10.3390/jcm9103213

Prior gestational diabetes mellitus (pGDM) is associated with increased risk of nonalcoholic fatty liver disease (NAFLD). Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists has shown beneficial effects in NAFLD patients. We evaluated th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc8ebb811d253f6ec0f6e168ca1c26a
https://curis.ku.dk/portal/da/publications/one-years-treatment-with-the-glucagonlike-peptide-1-receptor-agonist-liraglutide-decreases-hepatic-fat-content-in-women-with-nonalcoholic-fatty-liver-disease-and-prior-gestational-diabetes-mellitus-in-a-randomized-placebocontrolled-trial(803706d8-9787-420a-aa72-72318800a41d).html

[Ultrasound is the first choice when chronic venous disease in the lower extremities is suspected]

Autor: Thor, Bechsgaard, Kristoffer Lindskov, Hansen, Charlotte, Strandberg, Lars, Lönn, Jørgen Arendt, Jensen, Michael Bachmann, Nielsen, Niels, Bækgaard

Publikováno v: Ugeskrift for laeger. 178(44)

Chronic venous disease affects one quarter of the population and is routinely examined with Doppler ultrasound. The veins are evaluated in terms of diameter, compressibility and blood flow. The examination is performed with the patient in the standin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::29976a51bca7ff188989b82f87c6b0c1
https://pubmed.ncbi.nlm.nih.gov/27808055